Component
Plasma endoxifen concentration
Plasma endoxifen concentration. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Plasma endoxifen was lower with BR-DIM than placebo in women taking tamoxifen.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/dim-research/28560655.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f4d3745a4c2211551e755b314eced209ac88e072b9e02cd97cbaa5eed8303f28", "start_char": 0, "end_char": 1823, "text_sha256": "f4d3745a4c2211551e755b314eced209ac88e072b9e02cd97cbaa5eed8303f28"}
- experimental_model
- Randomized double-blind placebo-controlled trial
- exposure
- BR-DIM 150 mg twice daily for 12 months
- limitations
- Biomarker and pharmacokinetic endpoints, not recurrence or survival. The causal enzyme mechanism and effect on tamoxifen clinical benefit were not determined.
- nutrient_topic
- Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect. · 3,3'-Diindolylmethane / DIM
- organism
- 130 women prescribed tamoxifen; 98 completed
- plain_language
- This interaction was measured in people; its effect on cancer outcomes was not established.
- primary_references
- [dim-p28560655] A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. (2017). https://pubmed.ncbi.nlm.nih.gov/28560655/ DOI: 10.1007/s10549-017-4292-7
- tissue_or_cell_type
- Estrogen biomarkers and tamoxifen metabolites
Diindolylmethane (DIM): formation, receptor signaling, metabolism and drug interactions (2026-09-17) · lines 1052–1063
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized double-blind placebo-controlled trial · source_derived_draft · unverified_draft
### dim-endoxifen-lower Plasma endoxifen was lower with BR-DIM than placebo in women taking tamoxifen. Condition category: normal nutrient_topic: Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect. plain_language: This interaction was measured in people; its effect on cancer outcomes was not established. organism: 130 women prescribed tamoxifen; 98 completed tissue_or_cell_type: Estrogen biomarkers and tamoxifen metabolites experimental_model: Randomized double-blind placebo-controlled trial limitations: Biomarker and pharmacokinetic endpoints, not recurrence or survival. The causal enzyme mechanism and effect on tamoxifen clinical benefit were not determined. exposure: BR-DIM 150 mg twice daily for 12 months evidence_span: {"source_cache": "artifacts/dim-research/28560655.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "f4d3745a4c2211551e755b314eced209ac88e072b9e02cd97cbaa5eed8303f28", "start_char": 0, "end_char": 1823, "text_sha256": "f4d3745a4c2211551e755b314eced209ac88e072b9e02cd97cbaa5eed8303f28"} [dim-p28560655] A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. (2017). https://pubmed.ncbi.nlm.nih.gov/28560655/ DOI: 10.1007/s10549-017-4292-7
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.